Welcome to our dedicated page for Danaher Corporation news (Ticker: DHR), a resource for investors and traders seeking the latest updates and insights on Danaher Corporation stock.
Danaher Corporation (NYSE: DHR) is a global life sciences and diagnostics innovator whose news flow is closely followed by investors, healthcare professionals and industry observers. The company regularly issues press releases on its financial performance, capital allocation decisions and participation in major healthcare conferences, providing insight into how its life sciences and diagnostics businesses are performing and evolving.
On this page, readers can find news about Danaher’s quarterly and annual results, including updates on revenue trends, non‑GAAP core revenue growth and adjusted earnings, as described in its earnings releases and related Form 8‑K filings. The company frequently hosts earnings conference calls and webcasts, and it posts accompanying slide presentations, non‑GAAP reconciliations and notes on historical and anticipated financial performance in its investors materials.
Danaher also announces regular quarterly cash dividends on its common stock and discloses share repurchase authorizations, giving shareholders visibility into its capital allocation approach. In addition, news items cover leadership and governance developments, such as planned transitions in senior executive roles and changes in board composition, as documented in the company’s communications and SEC reports.
Beyond financial and corporate updates, Danaher’s news includes product and research announcements from its operating companies. For example, Beckman Coulter Diagnostics, a Danaher company, has reported the launch of a fully automated Brain‑derived Tau research use only immunoassay test and the development of an Aβ‑42 research use only immunoassay test to support neurodegenerative disease research. These stories illustrate how Danaher’s diagnostics businesses contribute to advanced clinical and research capabilities.
By reviewing the DHR news feed, users can monitor earnings announcements, dividend declarations, conference presentations, governance updates and scientific developments across Danaher’s life sciences and diagnostics platform. This page can be a useful resource for tracking how the company communicates its strategy, performance and innovation activities over time.
Danaher Corporation (NYSE: DHR) has declared a regular quarterly cash dividend of $0.32 per share of common stock. The dividend will be paid on July 25, 2025 to shareholders who are recorded as holders on June 27, 2025. This announcement represents the company's commitment to returning value to shareholders through consistent dividend payments.
Kytopen and Aldevron have announced a joint marketing agreement to enhance cell therapy manufacturing workflows. The collaboration combines Aldevron's Nanoplasmid vector technology with Kytopen's Flowfect Tx GMP platform for CRISPR-mediated T-cell engineering.
Key benefits of this partnership include:
- High transgene expression and improved safety from Nanoplasmid technology
- Gentle gene delivery with unlimited scale through Flowfect continuous flow technology
- Enhanced CRISPR-mediated T-cell engineering with higher yields
- Cost-effective and time-saving manufacturing process
The companies will present their joint findings at the International Society of Cell & Gene Therapy Annual Meeting in New Orleans (May 7-10, 2025). The presentation will showcase increased overall yield of final drug substance and easier manufacturing compared to viral and electroporation technologies.
Danaher (NYSE: DHR) has reported its Q1 2025 financial results, with net earnings of $1.0 billion ($1.32 per diluted share) and non-GAAP adjusted diluted earnings of $1.88 per share. Revenues saw a slight decrease of 1.0% to $5.7 billion, while non-GAAP core revenue remained flat year-over-year. The company generated strong cash flows with operating cash flow of $1.3 billion and non-GAAP free cash flow of $1.1 billion.
Looking ahead, Danaher expects low-single-digit core revenue growth for Q2 2025 and maintains its full-year 2025 core revenue growth projection of approximately 3%. The company has initiated full-year adjusted diluted earnings guidance of $7.60 to $7.75 per share.
Danaher (NYSE: DHR) has announced its upcoming first quarter 2025 earnings conference call, scheduled for Tuesday, April 22, 2025, at 8:00 a.m. ET. The hour-long presentation will include discussions on financial performance and future expectations.
The event will be accessible through a webcast on Danaher's website under the 'Investors' section, accompanied by slide presentations. Participants can join via phone by dialing 800-245-3047 (U.S.) or +1 203-518-9765 (international) using Conference ID: DHRQ125.
A replay will be available until May 6, 2025. The earnings press release, webcast slides, and related materials will be posted on Danaher's website at 6:00 a.m. ET on the day of the call.
Beckman Coulter Diagnostics has received FDA 510(k) clearance for its new DxC 500i Clinical Analyzer, an integrated clinical chemistry and immunoassay system. The analyzer features:
- Throughput capacity of 800 clinical chemistry tests and 100 immunoassay tests per hour
- FlexMode operations for test prioritization
- Dynamic sample handler for automated repeats and re-runs
- Intuitive interface with proactive task indicators
The system is designed to support networked laboratory operational models, particularly relevant as approximately 45% of U.S. clinical laboratories (over 11,000) are part of Integrated Delivery Networks (IDNs). The analyzer has been available in CE mark countries since July 2024 and builds upon the previously released DxC 500 AU Chemistry Analyzer technology.
Danaher (NYSE: DHR) has announced that its President and CEO, Rainer M. Blair, will deliver a presentation at the upcoming TD Cowen Healthcare Conference in Boston, Massachusetts. The presentation is scheduled for Wednesday, March 5, 2025, at 10:30 a.m. ET.
The event will feature a simultaneous webcast accessible to interested parties through the 'Investors' section of Danaher's website under 'Events & Presentations' at www.danaher.com.
Danaher (NYSE: DHR) has appointed Charles Lamanna to its Board of Directors and the Board's Science & Technology Committee. Lamanna currently serves as Corporate Vice President, Business & Industry Copilot at Microsoft, where he leads product innovation in AI-powered business applications, low-code platforms, and autonomous agents.
Lamanna oversees design, product development, and engineering of Microsoft's key technologies, including Power Platform, Dynamics 365, and Copilot Studio. He previously founded MetricsHub, a public cloud management solution acquired by Microsoft in 2013. The Notre Dame computer science graduate brings significant AI and technology expertise to Danaher's board as the company aims to leverage artificial intelligence to improve human health and deliver long-term stakeholder value.
Danaher (NYSE: DHR) has announced an increase in its regular quarterly cash dividend. The Board of Directors approved a dividend of $0.32 per share of common stock, representing an 18.5% increase from the previous payment of $0.27. The dividend will be payable on April 25, 2025 to shareholders of record as of March 28, 2025.
TriLink BioTechnologies, a Maravai LifeSciences (NASDAQ: MRVI) company, has entered into a non-exclusive License and Supply Agreement with Aldevron for CleanCap® mRNA capping technology. The agreement allows Aldevron to use TriLink's patented CleanCap® analogs in mRNA development and manufacturing services through Phase III programs.
The agreement covers CleanCap® M6, CleanCap® AG 3'OMe, CleanCap® AG, and CleanCap® AU cap analogs. The CleanCap® technology delivers optimal 5'Cap structures with over 95% efficiency, improving mRNA yield and process time compared to traditional methods. The technology has been used in over 350 preclinical and clinical programs and is featured in most approved COVID-19 mRNA and saRNA vaccines.
Notably, the recently introduced CleanCap® M6 (May 2023) has demonstrated increased mRNA expression by more than 30% compared to enzymatic capping methods.
Danaher (NYSE: DHR) reported its Q4 and full-year 2024 results, showing mixed performance. In Q4 2024, revenues increased 2.0% year-over-year to $6.5 billion, with non-GAAP core revenue up 1.0%. Q4 net earnings reached $1.1 billion, or $1.49 per diluted share, with non-GAAP adjusted EPS of $2.14.
For full-year 2024, the company reported flat revenues at $23.9 billion, while non-GAAP core revenue decreased 1.5%. Net earnings were $3.9 billion, or $5.29 per diluted share, with non-GAAP adjusted EPS of $7.48. Operating cash flow was strong at $6.7 billion, with free cash flow of $5.3 billion.
Looking ahead to 2025, Danaher expects Q1 core revenue to decline low-single digits year-over-year, but projects full-year core revenue growth of approximately 3%.